TNF-α抑制剂注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/注射用依那西普致葡萄膜炎2例分析

doi:10.19803/j.1672-8629.20230281

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (4): 457-460.
DOI: 10.19803/j.1672-8629.20230281

TNF-α抑制剂注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/注射用依那西普致葡萄膜炎2例分析

孙武, 陈水龄, 周婉瑜, 史航, 刘璐, 贺严, 付文涛, 褚利群^*

中国中医科学院西苑医院眼科,北京 100091

收稿日期:2023-05-09 出版日期:2024-04-15 发布日期:2024-04-18
通讯作者: ^*褚利群,男,博士,主任医师,眼科学。E-mail: chuliqunok@126.com
作者简介:孙武,男,博士,主治医师,眼科学。
基金资助:
中国中医科学院科技创新工程针灸临床学科重大攻关项目（C12021A03513）; 北京市自然科学基金资助项目（7244501）; 北京市中医药科技发展资金项目（BJZYYB -2023-77）

Two cases of uveitis caused by TNF-α inhibitor recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein for injection / etanercept for injection

SUN Wu, CHEN Shuiling, ZHOU Wanyu, SHI Hang, LIU Lu, HE Yan, FU Wentao, CHU Liqun^*

Ophthalmic Department, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China

Received:2023-05-09 Online:2024-04-15 Published:2024-04-18

摘要/Abstract

摘要： 目的探讨TNF-α抑制剂与葡萄膜炎发病的关系并分析TNF-α抑制剂诱发性葡萄膜炎的临床特点。方法回顾性分析2021年7月至2023年2月某院收治的2例使用TNF-α抑制剂注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白注射用依那西普后出现葡萄膜炎患者的临床特征并复习相关文献。结果 2例患者葡萄膜炎发生时间分别在用药后2周和6周,其中前葡萄膜炎1例,前、中间葡萄膜炎1例,经对症治疗后均有好转。在持续生物制剂治疗过程中2例患者均有反复发作倾向。查阅文献发现目前引起葡萄膜炎的TNF-α抑制剂主要包括英夫利昔单抗、阿达木单抗等,多用于治疗类风湿性关节炎、肿瘤、强直性脊柱炎、眼内葡萄膜炎患者等。患者年龄区间在5~77岁,发病时间为用药后1周~4年。经系统治疗,停止免疫抑制剂后,绝大多数诱发性葡萄膜炎患者视力可恢复。结论 TNF-α抑制剂可以诱发葡萄膜炎的发生,发病类型以前葡萄膜炎为主,且有复发倾向。及时诊疗后患者的视力预后较好。

关键词: TNF-α抑制剂, 注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/注射用依那西普, 葡萄膜炎, 副作用, 英夫利昔单抗, 阿达木单抗, 视力

Abstract: Objective To investigate the correlations between TNF-α inhibitor and uveitis and to analyze the clinical features of TNF-α inhibitor-induced uveitis. Methods The clinical data of 2 patients with uveitis treated with the recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein / ETANERCEPT for injection in our hospital between July 2021 and February 2023 was retrospectively analyzed, and the related literature was reviewed. Results Two female patients were collected. The onset of uveitis occurred at 2 and 6 weeks after medication, respectively, with one case of anterior uveitis and one case of anterior and intermediate uveitis. The conditions of both patients improved after symptomatic treatment. Literature review revealed that TNF-α inhibitors that caused uveitis included infliximab, adalimumab, and ETANERCEPT, which were mostly used for the treatment of rheumatoid arthritis, tumor, ankylosing spondylitis, and uveitis. The patients ranged from 5 to 77 in age, and the duration of onset ranged from 1 week to 4 years after medication. The vast majority of patients with TNF-α inhibitors-induced uveitis could recover their vision after systematic treatment and cessation of immunosuppressive agents. Conclusion The occurrence of uveitis is closely related to the use of TNF-α inhibitors, and the type of uveitis is predominantly anterior uveitis with a high chance of recurrence. Most patients have a favorable visual prognosis after prompt diagnosis and treatment.

Key words: TNF-α inhibitor, recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein / ETANERCEPT for injection, uveitis, side effects, infliximab, adalimumab, vision

中图分类号:

R988.1

孙武, 陈水龄, 周婉瑜, 史航, 刘璐, 贺严, 付文涛, 褚利群. TNF-α抑制剂注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/注射用依那西普致葡萄膜炎2例分析[J]. 中国药物警戒, 2024, 21(4): 457-460.

SUN Wu, CHEN Shuiling, ZHOU Wanyu, SHI Hang, LIU Lu, HE Yan, FU Wentao, CHU Liqun. Two cases of uveitis caused by TNF-α inhibitor recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein for injection / etanercept for injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 457-460.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.zgywjj.com/CN/10.19803/j.1672-8629.20230281

https://www.zgywjj.com/CN/Y2024/V21/I4/457

参考文献

[1] LEONE GM, MANGANO K, PETRALIA MC, et al.Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J]. J Clin Med, 2023, 12(4): 1630.
[2] SAMALIA P, SIMS J, NIEDERER R.Drug-induced ocular inflammation[J]. N Z Med J, 2020, 133(1527): 83-94.
[3] ABDALLA ELSAYED MEA, KOZAK I.Pharmacologically induced uveitis[J]. Surv Ophthalmol, 2021, 66(5): 781-801.
[4] LIM LL, FRAUNFELDER FW, ROSENBAUM JT.Do tumor necrosis factor inhibitors cause uveitis? A registry-based study[J]. Arthritis Rheum, 2007, 56(10): 3248-3252.
[5] WENDLING D, PACCOU J, BERTHELOT JM, et al.New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases[J]. Semin Arthritis Rheum, 2011, 41(3): 503-510.
[6] MOORTHY RS, MOORTHY MS, JR CUNNINGHAM ET.Drug-induced uveitis[J]. Curr Opin Ophthalmol, 2018, 29(6): 588-603.
[7] CHOI EY, LEE M, LEE CS.Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients[J]. Clin Exp Rheumatol, 2020, 38(6): 1132-1137.
[8] ABDALLA ELSAYED MEA, KOZAK I.Pharmacologically induced uveitis[J]. Surv Ophthalmol. 2021, 66(5): 781-801.
[9] EL-SHABRAWI Y, WEGSCHEIDER BJ, WEGER M, et al.Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations[J]. Ophthalmology, 2006, 113(4): 695-700.
[10] RAMOS-CASALS M, PEREZ-ALVAREZ R, DIAZ-LAGARES C, et al.Autoimmune diseases induced by biological agents: A double-edged sword?[J]. Autoimmun Rev, 2010, 9: 188-93.
[11] VERGOUWEN DPC, ROTHOVA A, BERGE JCT, et al.Current insights in the pathogenesis of scleritis[J]. Exp Eye Res, 2020, 197: 108078.
[12] GAUJOUX-VIALA C, GIAMPIETRO C, GAUJOUX T, et al.Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease[J]. J Rheumatol, 2012, 39(2): 233-239.
[13] SMITH JR, HART PH, COSTER DJ, et al.Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis[J]. Invest Ophthalmol Vis Sci, 1998, 39(3): 658-661.
[14] DAVIES R, DE COCK D, KEARSLEY-FLEET L, et al.The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data[J]. Rheumatology (Oxford), 2020, 59(6): 1391-1397.
[15] RAWAT BPS, JAGANNATHA A, LIU F, et al.Inferring ADR causality by predicting the Naranjo Score from Clinical Notes[J]. AMIA Annu Symp Proc, 2021, 2020: 1041-1049.
[16] TANTIKUL C, DHANA N, JONGJAREARNPRASERT K, et al.The utility of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of adverse drug reactions in hospitalized children[J]. Asian Pac J Allergy Immunol, 2008, 26(2-3): 77-82.
[17] SHUKLA AK, JHAJ R, MISRA S, et al.Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions[J]. J Family Med Prim Care, 2021, 10(9): 3303-3308.
[18] SIVAGOUROUNADIN K, RAJENDRAN P, SELVARAJAN S, et al.Agreement among different scales for causality assessment in drug-induced stevens-johnson syndrome and toxic epidermal necrolysis[J]. Curr Drug Saf, 2022, 17(1): 40-46.

TNF-α抑制剂注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白/注射用依那西普致葡萄膜炎2例分析

Two cases of uveitis caused by TNF-α inhibitor recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein for injection / etanercept for injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

[1]	任娱亲, 李歆, 余敏, 苏钰文. 基于OpenFDA的利妥昔单抗和阿达木单抗安全性评价与比较分析[J]. 中国药物警戒, 2022, 19(7): 752-756.
[2]	房城, 徐晓敏, 刘树民. 薯蓣皂苷药理学与毒理学研究进展[J]. 中国药物警戒, 2022, 19(4): 456-459.
[3]	王媛, 王平平, 郭桂丽, 冯英楠, 马青峰. 替罗非班致重度血小板减少1例及文献分析[J]. 中国药物警戒, 2022, 19(10): 1140-1144.
[4]	陈建寿, 王敏. 注射用硫酸多粘菌素B致皮肤色素沉着1例分析[J]. 中国药物警戒, 2021, 18(5): 489-491.
[5]	蔡俊, 卫菁, 纪立伟. 阿达木单抗致结核文献分析[J]. 中国药物警戒, 2018, 15(11): 682-685.
[6]	石亮,黄娜娜,孙晓倩,李晓宇,孙蓉. 柴胡水提组分对大鼠解热及伴随毒副作用实验研究[J]. 中国药物警戒, 2015, 12(4): 203-206.
[7]	李晓宇,孙蓉. 山豆根水提组分对实热证小鼠抗炎及伴随毒副作用机制研究[J]. 中国药物警戒, 2015, 12(2): 82-85.
[8]	尹利顺,吕莉莉,窦立雯,李晓宇,孙蓉. 山豆根水提组分对实热证小鼠抗炎及伴随毒副作用研究[J]. 中国药物警戒, 2015, 12(2): 79-81.
[9]	罗栋, 孙蓉. 北豆根不同组分对小鼠抗炎作用下的伴随毒副作用研究[J]. 中国药物警戒, 2012, 9(8): 449-452.
[10]	孙蓉, 黄伟. 吴茱萸水提组分镇痛及伴随毒副作用研究[J]. 中国药物警戒, 2012, 9(11): 641-644.
[11]	杨倩, 吕莉莉, 张丽美, 孙蓉. 鸦胆子不同组分抗炎与伴随毒副作用研究[J]. 中国药物警戒, 2011, 8(6): 336-338.
[12]	杨倩, 郑丽娜, 谢元璋, 孙蓉. 鸦胆子不同组分抗炎药效伴随毒副作用机制研究[J]. 中国药物警戒, 2011, 8(6): 333-335.